|
|
||||||||
J Thorac Cardiovasc Surg 1999;117:605-611
© 1999 Mosby, Inc.
GENERAL THORACIC SURGERY |
From First Department of Surgery, Osaka University Medical School,a Osaka; The Department of Surgery, Osaka Chuo Hospital,b Osaka; The Second Department of Surgery, Nagoya City University, Medical School,c Aichi; and the Department of Surgery, Ohtemae Hospital,d Osaka, Japan.
Received for publication April 21, 1998. Rrevisions requested June 17, 1998. Revisions received Oct 16, 1998. Accepted for publication Oct 19, 1998. Address for reprints: Shinichiro Miyoshi, MD, First Department of Surgery, E-1, Osaka University Medical School, 2-2 Yamada-Oka, Suita-City, Osaka 565-0871, Japan.
Objective: The purpose of this study is to clarify the significance of the particular involved organ as a prognostic factor and its relation to other previously reported factors.
Methods: The prognoses of 194 consecutive patients with thymoma who had undergone complete or subtotal resection were reviewed retrospectively. Survival was evaluated as actuarial freedom from tumor death. Analysis of prognostic factors was performed by the Kaplan-Meier method with the log rank test and Cox's proportional hazards model.
Results: The Masaoka staging system and involvement of the great vessels were the independent prognostic factors in the entire study group; age, sex, histologic subtype, completeness of resection, association of myasthenia gravis, or involvement of other organs were not factors. The 10-year and 20-year survivals were 99% and 90% in stage I, 94% and 90% in stage II, 88% and 56% in stage III, 30% and 15% in stage IVa, 0% and 0% in stage IVb, 93% and 83% in the absence of involvement of the great vessels, and 54% and 20% in the presence of it. Involvement of the great vessels was also the single independent prognostic factor in the patients with stage III disease although completeness of resection or involvement of other organs were not. The 10-year and 20-year survivals in patients with stage III disease were 97% and 75% in the absence of involvement of the great vessels, and 70% and 29% in the presence of it.
Conclusion: Although the Masaoka staging system is a valuable prognostic factor, the category of stage III is heterogeneous and consists of 2 groups with distinct prognoses depending on involvement of the great vessels.
This article has been cited by other articles:
![]() |
T. Utsumi, H. Shiono, A. Matsumura, H. Maeda, M. Ohta, H. Tada, A. Akashi, and M. Okumura Stage III thymoma: Relationship of local invasion to recurrence J. Thorac. Cardiovasc. Surg., December 1, 2008; 136(6): 1481 - 1485. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-i. Takeda, M. Koma, and H. Maeda Huge thymoma: role of preoperative WHO histological classification Interactive CardioVascular and Thoracic Surgery, December 1, 2008; 7(6): 1196 - 1198. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Davenport and R. A. Malthaner The role of surgery in the management of thymoma: a systematic review. Ann. Thorac. Surg., August 1, 2008; 86(2): 673 - 684. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Utsumi and M. Okumura A Staging System for Thymic Epithelial Tumors: More Discussion is Required. Ann. Thorac. Surg., September 1, 2006; 82(3): 1170 - 1170. [Full Text] [PDF] |
||||
![]() |
K. Kondo Invited commentary Ann. Thorac. Surg., December 1, 2005; 80(6): 2000 - 2001. [Full Text] [PDF] |
||||
![]() |
C. D. Wright, J. C. Wain, D. R. Wong, D. M. Donahue, H. A. Gaissert, H. C. Grillo, and D. J. Mathisen Predictors of recurrence in thymic tumors: Importance of invasion, World Health Organization histology, and size J. Thorac. Cardiovasc. Surg., November 1, 2005; 130(5): 1413 - 1421. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Venuta, T. de Giacomo, C. Andreetti, and G. Furio Coloni Transsternal thymoma resection MMCTS, April 25, 2005; 2005(0425): 182. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kondo and Y. Monden Thymoma and Myasthenia Gravis: A Clinical Study of 1,089 Patients From Japan Ann. Thorac. Surg., January 1, 2005; 79(1): 219 - 224. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-i. Takeda, N. Sawabata, M. Inoue, M. Koma, H. Maeda, and H. Hirano Thymic carcinoma. Clinical institutional experience with 15 patients Eur. J. Cardiothorac. Surg., August 1, 2004; 26(2): 401 - 406. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. C. Detterbeck and A. M. Parsons Thymic tumors Ann. Thorac. Surg., May 1, 2004; 77(5): 1860 - 1869. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Venuta, E. A. Rendina, F. Longo, T. De Giacomo, M. Anile, E. Mercadante, L. Ventura, M. F. Osti, F. Francioni, and G. F. Coloni Long-term outcome after multimodality treatment for stage III thymic tumors Ann. Thorac. Surg., December 1, 2003; 76(6): 1866 - 1872. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Santana, A. Givica, and C. Camacho Best Cases from the AFIP: Thymoma RadioGraphics, October 1, 2002; 22(90001): S95 - 102. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |